Wustmann N, Seitzer K, Humberg V, Vieler J, Grundmann N, Steinestel J
Biomark Res. 2023; 11(1):37.
PMID: 37016463
PMC: 10074820.
DOI: 10.1186/s40364-023-00481-w.
Zhao S, Liao J, Zhang S, Shen M, Li X, Zhou L
Front Oncol. 2023; 13:1053111.
PMID: 36865799
PMC: 9972874.
DOI: 10.3389/fonc.2023.1053111.
Derderian S, Vesval Q, Wissing M, Hamel L, Cote N, Vanhuyse M
Clin Transl Sci. 2022; 15(11):2597-2612.
PMID: 36172886
PMC: 9652435.
DOI: 10.1111/cts.13372.
Schlack K, Seitzer K, Wustmann N, Humberg V, Grundmann N, Steinestel J
Sci Rep. 2022; 12(1):11846.
PMID: 35831403
PMC: 9279395.
DOI: 10.1038/s41598-022-16094-6.
Wang C, Liu X, Li H, Zhao L, Kong G, Chen J
Transl Androl Urol. 2022; 11(2):202-212.
PMID: 35280667
PMC: 8899142.
DOI: 10.21037/tau-21-1136.
Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial.
Pathmanandavel S, Crumbaker M, Yam A, Nguyen A, Rofe C, Hovey E
J Nucl Med. 2021; 63(4):560-566.
PMID: 34326127
PMC: 8973290.
DOI: 10.2967/jnumed.121.262552.
The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
Liu R, Hu Q, Li S, Mao W, Xu B, Chen M
Technol Cancer Res Treat. 2021; 20:15330338211035260.
PMID: 34313171
PMC: 8320551.
DOI: 10.1177/15330338211035260.
Whole blood expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.
Kwan E, Fettke H, Crumbaker M, Docanto M, To S, Bukczynska P
Transl Androl Urol. 2021; 10(4):1688-1699.
PMID: 33968657
PMC: 8100842.
DOI: 10.21037/tau-20-1444.
The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis.
Wang Z, Shen H, Ma N, Li Q, Mao Y, Wang C
Front Oncol. 2021; 10:572590.
PMID: 33425724
PMC: 7793884.
DOI: 10.3389/fonc.2020.572590.
Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Wang J, Zhang Y, Wei C, Gao X, Yuan P, Gan J
Front Oncol. 2020; 10:562504.
PMID: 33330031
PMC: 7735106.
DOI: 10.3389/fonc.2020.562504.
Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate.
Stuopelyte K, Sabaliauskaite R, Bakavicius A, Haflidadottir B, Visakorpi T, Vaananen R
J Urol. 2020; 204(1):71-78.
PMID: 32068491
PMC: 7301408.
DOI: 10.1097/JU.0000000000000803.
A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jan Y, Yoon J, Chen J, Teng P, Yao N, Cheng S
Theranostics. 2019; 9(10):2812-2826.
PMID: 31244925
PMC: 6568173.
DOI: 10.7150/thno.34485.
Current strategies for targeting the activity of androgen receptor variants.
Armstrong C, Gao A
Asian J Urol. 2019; 6(1):42-49.
PMID: 30775247
PMC: 6363599.
DOI: 10.1016/j.ajur.2018.07.003.
Genetics and biology of prostate cancer.
Wang G, Zhao D, Spring D, DePinho R
Genes Dev. 2018; 32(17-18):1105-1140.
PMID: 30181359
PMC: 6120714.
DOI: 10.1101/gad.315739.118.
Regulation of ELL2 stability and polyubiquitination by EAF2 in prostate cancer cells.
Yang T, Jing Y, Dong J, Yu X, Zhong M, Pascal L
Prostate. 2018; 78(15):1201-1212.
PMID: 30009504
PMC: 6537586.
DOI: 10.1002/pros.23695.
Prostate cancer: AR-Vs not predictive in mCRPC.
Thoma C
Nat Rev Urol. 2018; 15(4):203.
PMID: 29485129
DOI: 10.1038/nrurol.2018.24.
